Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

Ghent University Hospital (UZ)

Status and phase: Completed; Phase 2

Conditions: Erosive Osteo-Arthritis

Treatments: Drug: Placebo; Drug: Adalimumab (40 mg sc every other week)

Study type: Interventional

Funder types: Other

Identifiers

NCT00296894

2006/072

Details and patient eligibility

About

Patients will be randomized into two groups (1/1) during one year:

• 40 mg adalimumab subcutaneously (sc) every other week
• placebo

The effect on x-rays and clinical parameters will be evaluated.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Clear erosive image on x-ray of at least one interphalangeal finger joint

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

Drug - adalimimab sc

Treatment:

Drug: Adalimumab (40 mg sc every other week)

2

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo